



**PRESS RELEASE  
FOR IMMEDIATE RELEASE**

---

**Medicago to Present at the Next Generation Vaccines 2008 Conference**

**Quebec City, Quebec, July 17, 2008** — Medicago Inc. (TSX-V:MDG) (the “Company”), today announced that it will be presenting an overview of its development of vaccines generated from plant-made Virus-Like Particles and unique technology platform at the Next Generation Vaccines 2008 Conference, held from July 17-18, 2008, at the Gaylord National Resort and Convention Center, National Harbor, Maryland.

Sonia Trepanier, Ph.D., Project Manager, Product Development will deliver a presentation on “An Innovative VLP-Based Technology for a Rapid and Efficient Pandemic Response,” in a session entitled “Development and Manufacturing of BioDefense Vaccines,” on Friday July 18, 2008 at 11:30 a.m. EDT.

Additional information about the Next Generation Vaccines 2008 Conference, including the full scientific program, can be viewed at [www.ibclifesciences.com/](http://www.ibclifesciences.com/).

**About Medicago**

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at [www.medicago.com](http://www.medicago.com).

***Forward- Looking Statements***

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

- 30 -

The TSX Venture Exchange assumes no responsibility for the content or accuracy of this press release

**Contact:**

**Medicago, Inc.**  
Andy Sheldon  
President and CEO  
(418) 658-9393

**Investor relations**

**The Equicom Group Inc.**  
Arianna Vanin  
(514) 844-4680  
[avanin@equicomgroup.com](mailto:avanin@equicomgroup.com)